Showing results (51-60 of 163) with videos related to

Sort By:
Pageof 17
Cancer Chemotherapy and Pharmacology|June 1, 2010
Phase I-II trial of prolonged gemcitabine infusion plus paclitaxel as a biweekly schedule for advanced breast cancer patients pretreated with anthracyclinesPatrizia Vici, Alessandra Fabi, Giulio Metro, et al.
Supportive Care in Cancer : Official Journal of the Multinational Association of Supportive Care in Cancer|May 15, 2008
Oral ondansetron is highly active as rescue antiemetic treatment for moderately emetogenic chemotherapy: results of a randomized phase II studyAlessandra Fabi, Mariangela Ciccarese, Giulio Metro, et al.
BMC Cancer|October 23, 2012
Maintenance bevacizumab beyond first-line paclitaxel plus bevacizumab in patients with Her2-negative hormone receptor-positive metastatic breast cancer: efficacy in combination with hormonal therapyAlessandra Fabi, Michelangelo Russillo, Gianluigi Ferretti, et al.
Clinical Lung Cancer|May 16, 2020
Treatment Patterns and Clinical Outcomes Among Patients With ROS1-rearranged Non-small-cell Lung Cancer Progressing on CrizotinibAndrea De Giglio, Giuseppe Lamberti, Francesco Facchinetti, et al.
Lung Cancer (Amsterdam, Netherlands)|May 12, 2018
Long-term survival with erlotinib in advanced lung adenocarcinoma harboring synchronous EGFR G719S and KRAS G12C mutationsBiagio Ricciuti, Sara Baglivo, Vienna Ludovini, et al.
Expert Review of Respiratory Medicine|December 31, 2015
Targeting the KRAS variant for treatment of non-small cell lung cancer: potential therapeutic applicationsBiagio Ricciuti, Giulia Costanza Leonardi, Giulio Metro, et al.
Human Vaccines & Immunotherapeutics|May 18, 2021
Immune checkpoint inhibitors for unresectable malignant pleural mesotheliomaGiulio Metro, Diego Signorelli, Elio G Pizzutilo, et al.
Oncology and Therapy|January 23, 2022
Inflamed Tumor Phenotype as Predictor of Long-Term Response to Pembrolizumab in an EGFR-Mutated Non-Small Cell Lung Cancer (NSCLC) Patient with Acquired Resistance to Afatinib: a Case Report and Review of the LiteratureSara Baglivo, Martina Mandarano, Guido Bellezza, et al.
Breast (Edinburgh, Scotland)|May 3, 2008
Do HER-2 positive metastatic breast cancer patients benefit from the use of trastuzumab beyond disease progression? A mono-institutional experience and systematic review of observational studiesAlessandra Fabi, Giulio Metro, Gianluigi Ferretti, et al.
Medical Oncology (Northwood, London, England)|April 19, 2018
Precision medicine against ALK-positive non-small cell lung cancer: beyond crizotinibBiagio Ricciuti, Andrea De Giglio, Carmen Mecca, et al.
Pageof 17